Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2024

Open Access 01-12-2024 | Osteoporosis | Research

Biochanin A abrogates osteoclastogenesis in type 2 diabetic osteoporosis via regulating ROS/MAPK signaling pathway based on integrating molecular docking and experimental validation

Authors: Qi He, Junzheng Yang, Weijian Chen, Zhaofeng Pan, Baihao Chen, Jiaxu Zeng, Nenling Zhang, Yuewei Lin, Chuyi Chen, Jiacong Xiao, Miao Li, Shaocong Li, Haibin Wang, Peng Chen

Published in: BMC Complementary Medicine and Therapies | Issue 1/2024

Login to get access

Abstract

Background

There are accumulating type 2 diabetes patients who have osteoporosis simultaneously. More effective therapeutic strategies should be discovered. Biochanin A (BCA) has been indicated that can play a role in improving metabolic disorders of type 2 diabetes and preventing osteoporosis. But whether BCA can treat type 2 diabetic osteoporosis has not been studied.

Purpose

To investigate if the BCA can protect against type 2 diabetic osteoporosis and clarify the mechanism.

Methods

Micro-CT and histology assays were performed to detect the trabecular bone and analyze the bone histomorphology effect of BCA. CCK-8 assay was performed to detect the toxicity of BCA. TRAcP staining, immunofluorescence and hydroxyapatite resorption assay were used to observe osteoclasts differentiation and resorptive activity. Molecular docking provided evidence about BCA regulating the MAPK axis via prediction by the algorithm. QRT-PCR and Western Blotting were utilized to detect the expression of osteoclastogenesis-related markers and MAPK signaling pathway.

Results

Accumulation of bone volume after BCA treatment could be found based on the 3D reconstruction. Besides, there were fewer osteoclasts in db/db mice treated with BCA than db/db mice treated with saline. In vitro, we found that BCA hadn’t toxicity in osteoclasts precursor, but also inhibited differentiation of osteoclasts. Further, we found that BCA suppresses osteoclastogenesis via ROS/MAPK signaling pathway.

Conclusion

BCA can prevent type 2 diabetic osteoporosis by restricting osteoclast differentiation via ROS/MAPK signaling pathway.
Appendix
Available only for authorised users
Literature
1.
Mohsin S, et al. An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther. 2019;19(9):937–48.PubMedCrossRef
2.
Vestergaard V. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos Int. 2007;18(4):427–44.PubMedCrossRef
3.
Schacter GI, Leslie WD. Diabetes and osteoporosis: part II, Clinical Management. Endocrinol Metab Clin North Am. 2021;50(2):287–97.PubMedCrossRef
4.
Tian S, et al. Modeling compound-target interaction network of traditional Chinese medicines for type II Diabetes Mellitus: insight for polypharmacology and drug design. J Chem Inf Model. 2013;53(7):1787–803.PubMedCrossRef
5.
Cui X, et al. Scutellariae Radix and Coptidis Rhizoma improve glucose and lipid metabolism in T2DM rats via regulation of the metabolic profiling and MAPK/PI3K/Akt signaling pathway. Int J Mol Sci. 2018;19(11):3634.PubMedCentralCrossRef
6.
Guo Q, et al. Study on hypoglycemic effect of the drug pair of Astragalus Radix and Dioscoreae Rhizoma in T2DM rats by Network Pharmacology and Metabonomics. Molecules. 2019;24(22):4050.PubMedPubMedCentralCrossRef
7.
Sun L, et al. Additional benefit of Chinese Medicine Formulae Including Dioscoreae rhizome (Shanyao) for Diabetes Mellitus: current state of evidence. Front Endocrinol (Lausanne). 2020;11:553288.PubMedCrossRef
8.
Wang S, et al. A comprehensive review on Pueraria: insights on its chemistry and medicinal value. Biomed Pharmacother. 2020;131:110734.CrossRef
9.
Ma R, et al. Diabetic osteoporosis: a review of its traditional Chinese medicinal use and clinical and preclinical research. Evid Based Complement Alternat Med. 2016;2016:3218313.PubMedCentralCrossRef
10.
Oza MJ, Kulkarni YA. Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 Diabetes. Biomed Pharmacother. 2018;107:1119–27.PubMedCrossRef
11.
Shen P, et al. Differential effects of isoflavones, from Astragalus Membranaceus and Pueraria Thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J Nutr. 2006;136(4):899–905.PubMedCrossRef
12.
Tan JW, Kim MK. Neuroprotective effects of Biochanin a against β-Amyloid-Induced neurotoxicity in PC12 cells via a mitochondrial-dependent apoptosis pathway. Molecules. 2016;21(5):548.PubMedPubMedCentralCrossRef
13.
Dubey RK, et al. 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension. 1998;31(1 Pt 2):522–8.PubMedCrossRef
14.
Siddiqui MT, Siddiqi M. Hypolipidemic principles of Cicer arietinum: biochanin-A and formononetin. Lipids. 1976;11(3):243–6.CrossRef
15.
Harini R, Ezhumalai M, Pugalendi KV. Antihyperglycemic effect of biochanin A, a soy isoflavone, on streptozotocin-diabetic rats. Eur J Pharmacol. 2012;676(1–3):89–94.PubMedCrossRef
16.
Su SJ, Yeh YT, Shyu HW. The preventive effect of biochanin a on bone loss in ovariectomized rats: involvement in regulation of growth and activity of osteoblasts and osteoclasts. Evid Based Complement Alternat Med. 2013;2013:594857.PubMedPubMedCentral
17.
18.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.PubMedPubMedCentralCrossRef
19.
Nguyen NT, et al. Autodock Vina adopts more accurate binding poses but Autodock4 forms better binding Affinity. J Chem Inf Model. 2020;60(1):204–11.PubMedCrossRef
20.
Zhang J, et al. Revealing synergistic mechanism of multiple components in gandi capsule for diabetic nephropathy therapeutics by network pharmacology. Evid Based Complement Alternat Med. 2018;2018:6503126.PubMedPubMedCentral
21.
Zhang L, et al. Network Pharmacology Approach to uncover the mechanism governing the Effect of Radix Achyranthis Bidentatae on Osteoarthritis. BMC Complement Med Ther. 2020;20(1):121.PubMedPubMedCentralCrossRef
22.
Veber DF, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.PubMedCrossRef
23.
Kumar R, et al. New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro. Sci Rep. 2017;7(1):10827.PubMedPubMedCentralCrossRef
24.
Rajendran V. Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1. Mol Biosyst. 2016;12(7):2276–87.CrossRef
25.
Rajendran V, Gopalakrishnan C, Sethumadhavan R. Pathological role of a point mutation (T315I) in BCR-ABL1 protein-A computational insight. J Cell Biochem. 2018;119(1):918–25.CrossRef
26.
27.
Qu B, et al. SIRT1 suppresses high glucose and palmitate-induced osteoclast differentiation via deacetylating p66Shc. Mol Cell Endocrinol. 2018;474:97–104.CrossRef
28.
Rharass T, Lucas S. High glucose level impairs human mature bone marrow adipocyte function through increased ROS production. Front Endocrinol (Lausanne). 2019;10:607.PubMedCrossRef
29.
Sun M, et al. TNF-α is upregulated in T2DM patients with fracture and promotes the apoptosis of osteoblast cells in vitro in the presence of high glucose. Cytokine. 2016;80:35–42.PubMedCrossRef
30.
31.
32.
Oza MJ, Kulkarni YA. Biochanin A attenuates cardiomyopathy in type 2 Diabetic rats by increasing SIRT1 expression and reducing oxidative stress. Chem Biodivers. 2022;19(3):e202100591.PubMedCrossRef
33.
Yang J, et al. Gegen Qinlian Decoction ameliorates type 2 Diabetes osteoporosis via IGFBP3/MAPK/NFATc1 signaling pathway based on cytokine antibody array. Phytomedicine. 2022;94:153810.PubMedCrossRef
34.
He Q, et al. Sanhuang Jiangtang tablet protects type 2 Diabetes osteoporosis via AKT-GSK3β-NFATc1 signaling pathway by integrating bioinformatics analysis and experimental validation. J Ethnopharmacol. 2021;273:113946.PubMedCrossRef
35.
Napoli N, et al. Mechanisms of Diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208–19.PubMedCrossRef
36.
Agidigbi TS, Kim C. Reactive oxygen species in Osteoclast differentiation and possible Pharmaceutical targets of ROS-Mediated Osteoclast Diseases. Int J Mol Sci. 2019;20(14):3576.PubMedPubMedCentralCrossRef
37.
Tao H, et al. ROS signaling cascades: dual regulations for osteoclast and osteoblast. Acta Biochim Biophys Sin (Shanghai). 2020;52(10):1055–62.PubMedCrossRef
38.
Kamata H, et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005;120(5):649–61.PubMedCrossRef
39.
Wei ZF, et al. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways. PLoS One. 2013;8(3):e59171.PubMedCentralCrossRef
40.
41.
Wong BR, et al. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem. 1998;273(43):28355–9.PubMedCrossRef
42.
Chiou WF, Huang YL, Liu YW. TRAF6 is poly-ubiquitinated after RANKL stimulation and RANKL-induced expression of NFATc1 in osteoclast differentiation is dependent on TRAF6. 2014.
43.
Matsuo K, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004;279(25):26475–80.PubMedCrossRef
44.
Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun. 2003;305(2):211–4.PubMedCrossRef
45.
46.
Balkan W, et al. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Gene. 2009;446(2):90–8.PubMedCrossRef
47.
Shen Z, et al. A novel promoter regulates calcitonin receptor gene expression in human osteoclasts. Biochim Biophys Acta. 2007;1769(11–12):659–67.PubMedCrossRef
Metadata
Title
Biochanin A abrogates osteoclastogenesis in type 2 diabetic osteoporosis via regulating ROS/MAPK signaling pathway based on integrating molecular docking and experimental validation
Authors
Qi He
Junzheng Yang
Weijian Chen
Zhaofeng Pan
Baihao Chen
Jiaxu Zeng
Nenling Zhang
Yuewei Lin
Chuyi Chen
Jiacong Xiao
Miao Li
Shaocong Li
Haibin Wang
Peng Chen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2024
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04332-x

Other articles of this Issue 1/2024

BMC Complementary Medicine and Therapies 1/2024 Go to the issue

Matters Arising

Responses to the correspondence from McDowell et al.’s on CAM integrative review of health care professionals in New Zealand

Research

TM-MC 2.0: an enhanced chemical database of medicinal materials in Northeast Asian traditional medicine

Research

Phytochemical and biological assessment of secondary metabolites isolated from a rhizosphere strain, Sphingomonas sanguinis DM of Datura metel

Research

The study of wound healing activity of Thespesia populnea L. bark, an approach for accelerating healing through nanoparticles and isolation of main active constituents

Correction

Correction: Exploring the antibacterial, antidiabetic, and anticancer potential of Mentha arvensis extract through in‑silico and in‑vitro analysis

Research

Protective effect of Tao Hong Si Wu Decoction against inflammatory injury caused by intestinal flora disorders in an ischemic stroke mouse model